{
    "name": "levoketoconazole",
    "comment": "Rx",
    "other_names": [
        "Recorlev"
    ],
    "classes": [
        "Cortisol Synthesis Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/recorlev-levoketoconazole-4000226",
    "pregnancy": {
        "common": [
            "Levoketoconazole is the 2S, 4R enantiomer of ketoconazole",
            "Available published data from case series and case-control studies on use of racemic ketoconazole during pregnancy are insufficient to determine drug-associated risk of major birth defects",
            "Data are unavailable regarding risk of miscarriage "
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "No animal reproduction studies conducted with levoketoconazole",
                    "Levoketoconazole constituted about 70% of exposure in humans and animals after racemic ketoconazole administration",
                    "Embryotoxic effects observed in pregnant mice, rats, and rabbits, and fetal malformations observed in rats, following oral dosing of racemic ketoconazole during organogenesis at doses equal and less than the maximum recommended human dose (MRHD), respectively"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "Active Cushing syndrome during pregnancy associated with increased risk of maternal and fetal morbidity and mortality, including gestational diabetes, gestational hypertension, preeclampsia, maternal death, miscarriage, intrauterine fetal demise, preterm birth, and neonatal death",
                    "  ",
                    "  ",
                    "Dystocia (difficult labor) observed in mice and rats administered oral ketoconazole during organogenesis at exposures below the MRHD of levoketoconazole (BSA)",
                    "Clinical relevance of these findings for humans is unknown"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "May lower testosterone and impair male and female fertility",
                    "Effect reversible upon discontinuation"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are unavailable regarding effects on milk production",
            "Data from 1 lactating woman show ketoconazole present in human milk in low amounts, with no reported adverse effects on the breastfed infant; however, these limited data are insufficient to determine risk to breastfed infants with exposure to ketoconazole through breast milk",
            "Advise patients not to breastfeed during treatment and for 1 day (5 half-lives) after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Hepatotoxicity",
                    "description": [
                        "Serious hepatotoxicity cases reported, some with fatal outcome or requiring liver transplantation",
                        "Some patients had no obvious risk factors for liver disease",
                        "Contraindicated in patients with cirrhosis, acute liver disease or poorly controlled chronic liver disease, recurrent symptomatic cholelithiasis, prior history of drug-induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease",
                        "Evaluate liver enzymes before and during treatment",
                        "Interrupt treatment immediately if signs of hepatotoxicity occur"
                    ]
                },
                {
                    "type": "QT prolongation",
                    "description": [
                        "Associated with dose-related QT interval prolongation",
                        "QT interval prolongation may lead to life-threatening ventricular dysrhythmias (eg, torsades de pointes)",
                        "Contraindicated with other drugs that prolong QT interval associated with ventricular arrhythmias, including torsades de pointes, and use in patients with prolonged QTcF interval >470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome (including first-degree family history)",
                        "Perform ECG and correct hypokalemia and hypomagnesemia before and during treatment",
                        "Temporarily discontinue levoketoconazole if QTcF interval >500 msec"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Cirrhosis, acute liver disease or poorly controlled chronic liver disease, baseline AST or ALT >3x ULN, recurrent symptomatic cholelithiasis, prior history of drug-induced liver injury due to ketoconazole or any azole antifungal therapy that required discontinuation of treatment, or extensive metastatic liver disease",
                "Coadministration with drugs that cause QT prolongation associated with ventricular arrhythmias, including torsades de pointes",
                "Prolonged QTcF interval >470 msec at baseline, history of torsades de pointes, ventricular tachycardia, ventricular fibrillation, or long QT syndrome (including first-degree family history)",
                "Known hypersensitivity to levoketoconazole, ketoconazole or any excipient in drug product",
                "Taking certain drugs that are sensitive substrates of CYP3A4 or CYP3A4 and P-glycoprotein (P-gp)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Serious hepatotoxicity reported, including fatal outcomes or requiring liver transplantation with use of oral ketoconazole, racemic mixture from which levoketoconazole is derived; prompt recognition of liver injury essential; educate patients on symptoms associated with hypocortisolism and advise them to contact a healthcare provider if they occur ",
                "Associated with dose-related QT interval prolongation (see contraindications, drug interactions, dosage modification, dosing considerations); use with caution in patients with other risk factors for QT prolongation, such as congestive heart failure, bradyarrythmias, and uncorrected electrolyte abnormalities, with more frequent ECG monitoring considered ",
                "Hypersensitivity reactions reported",
                "May lower serum testosterone in men and women; potential clinical manifestations of decreased testosterone concentrations in men may include gynecomastia, impotence and oligospermia; potential clinical manifestations of decreased testosterone concentrations in women include decreased libido and mood changes"
            ],
            "specific": [
                {
                    "type": "Hypocortisolism",
                    "description": [
                        "Levoketoconazole lowers cortisol levels and may lead to hypocortisolism with a potential for life-threatening adrenal insufficiency",
                        "Lowering of cortisol levels can cause nausea, vomiting, fatigue, abdominal pain, loss of appetite, and dizziness",
                        "Significant lowering of serum cortisol levels may result in adrenal insufficiency that can be manifested by hypotension, abnormal electrolyte levels, and hypoglycemia",
                        "Stop levoketoconazole and administer exogenous glucocorticoid replacement therapy if morning serum or plasma cortisol levels are below target range and signs and/or symptoms of adrenal insufficiency, or hypocortisolism, are present",
                        "After discontinuation, cortisol suppression may persist beyond the 4-6 hr half-life of levoketoconazole"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "CYP3A4 substrate (major); strong CYP3A4 inhibitor",
                        "QT prolonging drugs",
                        "Contraindicated in patients taking other drugs known to cause QT interval prolongation associated with ventricular arrhythmias, including torsades de pointes",
                        "CYP3A4 or CYP3A4/P-gp substrates that prolong QT",
                        "Contraindicated with CYP3A4 and/or P-gp substrates that cause QT prolongation associated with ventricular arrhythmias, including torsades de pointes",
                        "Levoketoconazole inhibits CYP3A4 and P-gp, which may increase substrate systemic exposure and risk for QT prolongation",
                        "Sensitive CYP3A4 or CYP3A4/P-gp substrates",
                        "Contraindicated or not recommended",
                        "Levoketoconazole inhibits CYP3A4 and P-gp, which may increase sensitive substrate systemic exposure",
                        "Atorvastatin",
                        "Reduce atorvastatin dose",
                        "Levoketoconazole increases plasma concentration of atorvastatin and may increase risk of atorvastatin-associated myopathy and rhabdomyolysis",
                        "Use lowest atorvastatin dose possible and monitor for adverse reactions when atorvastatin dose >20 mg/day ",
                        "Metformin and other OCT2 and MATE substrates",
                        "Monitor",
                        "Levoketoconazole increases metformin concentration and may increase risk of metforminâ€™s adverse reactions; may increase plasma concentrations of other OCT2 and MATE substrates and increase risk of their adverse reactions",
                        "During levoketoconazole dosage titration, monitor blood glucose, kidney function, and vitamin B12 per metformin prescribing information and adjust metformin dosage as needed",
                        "Strong CYP3A4 inhibitors",
                        "Not recommended",
                        "May increase plasma concentration of levoketoconazole and increase risk of adverse effects",
                        "Avoid use of these drugs from 2 weeks before and during treatment",
                        "Strong CYP3A4 inducers",
                        "Not recommended",
                        "May decrease plasma concentration of levoketoconazole and decrease efficacy",
                        "Avoid use of these drugs from 2 weeks before and during treatment",
                        "Gastric acid neutralizers",
                        "Take gastric acid neutralizer (eg, aluminum hydroxide) at least 2 hr after levoketoconazole",
                        "Impairs levoketoconazole absorption",
                        "Gastric acid suppressors or sucralfate",
                        "Avoid",
                        "Gastric acid suppressors (eg, H2 antagonists, PPIs) and sucralfate impair levoketoconazole absorption",
                        "Alcohol",
                        "Avoid excessive consumption",
                        "Disulfiram-like reactions reported"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "AST",
            "percent": "45"
        },
        {
            "name": "ALT",
            "percent": "1"
        },
        {
            "name": "ULN",
            "percent": "27"
        },
        {
            "name": "liver related adverse reaction",
            "percent": "20"
        },
        {
            "name": "Liver enzyme elevation",
            "percent": "3"
        },
        {
            "name": "AST",
            "percent": "11"
        },
        {
            "name": "ALT",
            "percent": "5"
        },
        {
            "name": "x ULN",
            "percent": "5"
        },
        {
            "name": "AST",
            "percent": "10"
        },
        {
            "name": "ALT",
            "percent": "3"
        },
        {
            "name": "x ULN",
            "percent": "4"
        },
        {
            "name": "AST",
            "percent": "2"
        },
        {
            "name": "ALT",
            "percent": "2"
        },
        {
            "name": "x ULN",
            "percent": "1"
        },
        {
            "name": "Hepatic pain",
            "percent": null
        },
        {
            "name": "Drug",
            "percent": null
        },
        {
            "name": "induced liver injury",
            "percent": null
        },
        {
            "name": "Liver disorders",
            "percent": null
        },
        {
            "name": "Hepatic steatosis",
            "percent": null
        }
    ]
}